Finding out I had limited treatment options for triple-negative breast cancer
I was 29 when I saw the words triple-negative breast cancer on my pathology report.
That night I did what most of us do. I typed it into Google. Within minutes the headlines piled up: Most aggressive form. Limited treatment options. Higher recurrence rate.
Looking back, those headlines weren't what hurt me most. It was what my mind did with the information. Within minutes, fear had turned a few lines on a screen into a verdict on what my future would hold. If that's happening to you right now, I'm not surprised, because that's what happened to me too.
It's what minds do when they feel they are under threat - they look for the negative in the things you read and hear in your environment.
Back then, those headlines weren't wrong. Triple-negative breast cancer doesn't have the three "targets" (estrogen, progesterone and HER2) that many breast cancer drugs aim at.
Many years ago, if you were diagnosed with triple-negative, chemotherapy was really the only drug treatment on offer. In my mind, chemo was my only shot at beating this, and if it didn't work, I would be out of options. Yikes!
Fifteen years later, you might still find those same scary headlines about triple negative breast cancer. That's partly because some of that information is out of date, and partly because fear feeds a scarcity mindset (more on that below).
Nevertheless, fear will make you ask the same question I did 15 years ago.
"Have I run out of treatment options?"
What you might not know is that there have been great strides in medical research and new treatment options are becoming more available for triple-negative breast cancer.
This post is for you if you've just been diagnosed, or if you love someone who has - so keep reading.
Here's what I'll cover:
I'll walk you through what's new in triple negative breast cancer treatment in plain English.
I'll give you a simple treatment table to take to your next appointment and a list of questions to discuss with your doctor.
Lastly, I want to show you how you can notice when fear is shrinking your options, and what you can do about it.
📌 Pin this article for later
Before we get into the science, try one small thing for me.
As you read, notice what your mind does with each new piece of information. Does it jump straight to that won't work for me? Or can it make a little room for what else might be possible? That tiny shift is where this whole post is heading.
A quick note before we start: I'm not a doctor, and this isn't medical advice. It's general information to help you have better conversations with your care team. Every cancer is different, and the right treatment for you is a decision you make with your oncologist.
What's changed: four kinds of treatment to know about in 2027
The biggest shift is that triple-negative is no longer treated as one single disease. Doctors now test your cancer, and often your genes, for extra clues. Those clues can open doors to smarter, more targeted treatments that didn't exist when I was diagnosed.
If a voice in your head is already saying none of this will apply to me, just notice it. That's a thought, not a fact. You don't have to argue with it yet. Read on, and let the facts have their say.
If you've just been diagnosed with early-stage cancer, numbers 1, 3 and 4 are the ones most likely to come up now. Number 2 is mostly used if cancer spreads or comes back.
1. Immunotherapy: helping your immune system see the cancer.
Your immune system has "brakes" that stop it attacking your own body. Cancer cells can press on those brakes to hide. Immunotherapy takes the brakes off, so your immune system can find the cancer and fight it.
If you have stage 2 or 3 triple-negative, it's often given with chemo before surgery, then on its own after surgery. In a large study called KEYNOTE-522, people who had it lived longer on average than people who had chemo alone (ESMO).
Drug name to know: pembrolizumab (brand name Keytruda).
2. Antibody-drug conjugates (ADCs): chemo with a homing device.
Think of a guided missile. One part locks onto a protein on the outside of the cancer cell. The other part is a chemo drug, which it carries straight into that cell. It's still chemo, and it still has side effects. But it's aimed much more precisely.
This is where most of the big 2026 news is. In the US, Datroway and Trodelvy were both approved in mid-2026 as a first treatment for triple-negative breast cancer that has spread (Breastcancer.org).
Drug names to know:
sacituzumab govitecan (Trodelvy): locks onto a protein called TROP2
datopotamab deruxtecan (Datroway): also locks onto TROP2
trastuzumab deruxtecan (Enhertu): locks onto HER2, for "HER2-low" cancers (more on this below)
3. PARP inhibitors: for people with a BRCA gene change.
About 70 to 80% of breast cancers in women with a BRCA1 gene change are triple-negative (Cleveland Clinic). A faulty BRCA gene means the cancer cells already find it hard to repair their DNA. PARP inhibitors block their backup repair route, so the cancer cells can't fix the damage.
This one is personal for me. I'm a BRCA1 carrier, and I only found out because I pushed for genetic testing.
Drug names to know: olaparib (Lynparza). Talazoparib (Talzenna) is another, used when the cancer has spread.
4. Extra treatment after surgery.
Sometimes cancer is still found at surgery, even after treatment beforehand. If that happens, there are now extra treatments to lower the chance of it coming back. New ones are being tested in trials right now.
Drug names to know:
capecitabine (Xeloda): a chemo tablet
olaparib (Lynparza): for some people with a BRCA gene change
One more thing worth knowing: "triple-negative" isn't always the whole story. Many triple-negative cancers have a small amount of HER2 on them. Doctors call this "HER2-low", and it can open the door to a treatment that works on HER2 (Facing Our Risk).
The news from the past year
In 2026 alone, the US approved two new first treatments for advanced triple-negative breast cancer, and at least two more new drugs reported positive large trials. Most of this news is about triple-negative that has spread or come back. If your cancer is early-stage, much of it may never apply to you, but it shows how fast this field is now moving.
| When | What happened | What it means in plain English |
|---|---|---|
| Oct 2026 | At the big European cancer meeting (ESMO), early results showed Datroway kept cancer in the brain in check for longer than chemo did, for triple-negative that had spread there (BCRF) | About a third of people with triple-negative develop brain spread, and it's been hard to treat. This is a hopeful first sign. |
| Oct 2026 | Final results for sacituzumab tirumotecan (sac-TMT) in people in China who'd already had other treatments (Pharmacy Times) | People on the new drug lived longer on average than people on chemo. |
| Aug 2026 | Europe approved Trodelvy plus Keytruda as a first treatment for advanced triple-negative that's PD-L1 positive (OncLive) | A new first option for people whose cancer responds to immunotherapy. |
| Aug 2026 | Australia: Trodelvy is on the PBS for people who've had at least two earlier treatments; Datroway is under TGA review, and the PBS committee considers it in November 2026 (healthdirect, PBS) | The newest options are on their way here too, though access differs by country. |
| Jun 2026 | US approved Trodelvy as a first treatment for advanced triple-negative: on its own, or with Keytruda if PD-L1 positive (Targeted Oncology) | A "guided missile" drug is now used at the start, not saved for later. |
| Jun 2026 | A brand-new type of drug, iza-bren, which aims at two targets at once, beat chemo in a large trial in China (CancerNetwork) | The cancer was held back nearly three times as long on average, and people lived longer. It's still experimental. |
| May 2026 | US approved Datroway as a first treatment for advanced triple-negative when immunotherapy isn't an option (AJMC) | About 7 in 10 people with advanced triple-negative can't have immunotherapy. Until now, chemo was their only first option. |
| May 2026 | sac-TMT also beat chemo as a first treatment in another large trial (CancerNetwork) | A third "TROP2" guided missile is on its way. |
These are averages from clinical trials, not predictions for any one person. Your oncologist is the best person to tell you what they might mean for you.
Your triple-negative treatment cheat sheet
Today there are at least 10 drugs and approaches either in use or in late-stage testing for triple-negative breast cancer. Save this table, or print it for your next appointment.
| Treatment (brand name) | Type | How it works, in plain English | Who it's used or studied for | Status (Nov 2026) |
|---|---|---|---|---|
| Chemotherapy (e.g. paclitaxel, carboplatin, doxorubicin) | Chemotherapy | Attacks cells that grow and divide fast, like cancer cells | Most people with triple-negative, often alongside the newer drugs below | Standard care everywhere |
| Pembrolizumab (Keytruda) | Immunotherapy | Takes the "brakes" off your immune system so it can find and attack the cancer | High-risk early stage (II–III): with chemo before surgery, then alone after. Advanced: with chemo or Trodelvy if the tumor is PD-L1 positive (score of 10 or more) | Approved |
| Capecitabine (Xeloda) | Chemotherapy tablet | A chemo you take at home, turned into its active form inside the body | Early stage, when some cancer is still found at surgery after pre-surgery chemo | Established option |
| Olaparib (Lynparza) or talazoparib (Talzenna) | PARP inhibitor (tablet) | Stops cancer cells with a faulty BRCA gene from repairing their DNA | People with an inherited BRCA1 or BRCA2 change: olaparib for one year after chemo in high-risk early stage; either drug for advanced cancer | Approved |
| Sacituzumab govitecan (Trodelvy) | ADC ("guided missile") aimed at TROP2 | Finds the TROP2 protein on cancer cells and delivers chemo straight inside | Advanced: as a first treatment (alone, or with Keytruda if PD-L1 positive), or after earlier treatments | US first-line approval Jun 2026; Europe (with Keytruda) Aug 2026; Australia PBS after 2+ earlier treatments |
| Datopotamab deruxtecan (Datroway) | ADC aimed at TROP2 | Same target as Trodelvy, with a different design and drug | Advanced: as a first treatment when immunotherapy isn't an option | US approved May 2026; under review in Australia |
| Trastuzumab deruxtecan (Enhertu) | ADC aimed at HER2 | Finds even small amounts of HER2 and delivers chemo inside | Advanced "HER2-low" cancer (HER2 score 1+ or 2+) after chemo for advanced disease | US approved 2022 |
| Sacituzumab tirumotecan (sac-TMT) | ADC aimed at TROP2 | A newer TROP2 guided missile with a different link between antibody and drug | Advanced cancer; also being tested after surgery when cancer remains | Positive large trials; still in trials in most countries |
| Izalontamab brengitecan (iza-bren) | "Bispecific" ADC aimed at EGFR and HER3 | Grabs two different targets on cancer cells at once | Advanced cancer after earlier treatment | Experimental; positive large trial in China |
| Alpha-lactalbumin vaccine | Vaccine | Trains the immune system to attack a protein found on most triple-negative cancers | Being tested in high-risk early stage and in BRCA carriers | Early research (phase 1) |
"Advanced" here means cancer that has spread or can't be removed with surgery. This table describes how each drug is approved or being studied, not who should take it. Availability, funding and rules differ by country, so ask your care team what applies where you live.
Reading this table might bring up a lot of feelings. If it does, that's normal. Stay with me, because the end of this post is about exactly that.
Six questions to take to your oncologist
The new treatments depend on clues your team may already have, or can test for. These questions help you find out which doors might be open to you.
Has my tumor been tested for PD-L1? What was the result? If the cancer has spread, this result helps decide whether immunotherapy is an option. (For stage 2 or 3, Keytruda is usually offered whatever the result.)
Is my cancer HER2-zero or HER2-low? "Triple-negative" can still be HER2-low, which matters if you ever need treatment for advanced cancer.
Should I have genetic testing for BRCA1, BRCA2 and similar genes? For me, this one question changed my whole surgery and radiation plan.
If cancer is still found at surgery, what's the plan after that?
Are there clinical trials I could join, now or later?
Which of these treatments are available and funded where I live?
Asking these doesn't make you a difficult patient. It makes you a partner in your own care.
If your mind tends to go blank the moment you sit down in that room, you're not alone. In my book I share the simple ritual I used before every appointment to stay calm and remember what I wanted to ask. Look inside the book →
The trick your mind plays: scarcity vs abundance
When I read "limited treatment options" that night, my brain didn't just take in a fact. It wrote a whole story: There's nothing for me. I'm running out of options.
That's a scarcity mindset. Fear shrinks your focus down to what's missing. It's an old survival habit, and it's very good at making a closed door look like a brick wall.
Here's what fifteen years have taught me. The scariest thing you read at 2am is often out of date. Medicine keeps moving, even on the nights you feel stuck.
An abundance mindset isn't pretending everything is fine. It's noticing what's actually there: more tests that tell your team about your cancer, more kinds of treatment, more trials, and more people who've walked this road before you.
This post was a mindset tool in disguise
In my book, Win the Fight Against Cancer, I share a five-step method I call FACTS. It's built on CBT (cognitive behavioural therapy), the same tools therapists use to help people untangle anxious thoughts.
Step four of this five-step process to dispel that 3am anxiety is to Test your fears against medical reality. That's what you just did. You took the thought "there are no options for triple-negative" and held it up against what's actually true right now.
But testing one fear is just the start. The other four steps help you catch the fear in the first place, see it as a thought rather than the truth, and argue with it like a lawyer. And then there's step five, which turned my diagnosis around in my head.
Your body has a treatment plan. Your mind needs one too.
You'll get plenty of guidance for treating your body. My book is for the fight no one prepares you for: the one in your mind.
It won't make cancer easy, and no book can promise how your story goes. But it gives you practical tools to steady your emotions, think clearly, and walk into your next appointment as a partner in your care, not a passenger.
If you're supporting someone with triple-negative breast cancer, it can also help you understand what's going on in their mind.
Win the Fight Against Cancer by Trifina Sofian is available in Kindle and paperback on Amazon.
Please talk to your care team before making any decisions about your treatment.
Sources
Datroway wins first-line FDA approval for immunotherapy-ineligible TNBC, AJMC, 22 May 2026
FDA approves Datroway as first-line treatment for metastatic TNBC, BCRF, 29 May 2026
FDA approves sacituzumab govitecan for first-line TNBC, Targeted Oncology, 24 Jun 2026
European Commission approves sacituzumab govitecan plus pembrolizumab, OncLive, 24 Aug 2026
Iza-bren improves OS/PFS in advanced TNBC (PANKU-Breast02), CancerNetwork, 2 Jun 2026
Sacituzumab tirumotecan meets PFS end point as first-line option (OptiTROP-Breast03), CancerNetwork, 22 May 2026
ESMO 2026 breast cancer round-up incl. OptiTROP-Breast01 final survival, Pharmacy Times, Oct 2026
Important breast cancer research updates from ESMO 2026 (Datroway and brain metastases), BCRF, Oct 2026
OlympiA long-term results for olaparib, AstraZeneca, Dec 2024
Enhertu improves survival for metastatic HER2-low breast cancer, National Cancer Institute, 2022
Cleveland Clinic updated findings in preventive breast cancer vaccine study, Nov 2024
Trodelvy on the PBS, healthdirect; Datroway PBS submission status, PBS